Therapeutic Potential of Triptolide in Treating Bone-Related Disorders

Overview

Journal Front Pharmacol

Date 2022 Jul 5

PMID 35784734

Authors

Wu Gang

Hu Hao

Huang Yong

Feng Ruibing

Li Chaowen

Huang Yizheng

Li Chao

Zhang Haitao

Affiliations

Soon will be listed here.

Abstract

Triptolide, a diterpene triepoxide, is a pharmacologically active compound isolated from a Chinese medicinal herb Hook F (TwHF). Triptolide has attracted considerable attention in recent times due to its multiple biological and pharmaceutical activities, with an emphasis on therapeutic importance in the treatment of diverse disorders. With essential medicinal implications, TwHF's extracts have been used as anti-inflammatory, antiproliferative, antioxidative, and immunosuppressive agents for centuries, with continuous and relevant modifications to date to enhance its utility in several diseases and pathophysiology. Here, in this review, we accentuate the studies, highlighting the effects of triptolide on treating bone-related disorders, both inflammatory and cancerous, particularly osteosarcoma, and their manifestations. Based on this review, future avenues could be estimated for potential research strategies, molecular mechanisms, and outcomes that might contribute toward reinforcing new dimensions in the clinical application of triptolide in treating bone-related disorders.

Citing Articles

Triptolide induces apoptosis of glioma cells by inhibiting NF-κB activation during oxidative stress.

Li X, Shan Y, Wang S, Wang J, Heng X Sci Rep. 2024; 14(1):29740.

PMID: 39614071 PMC: 11607343. DOI: 10.1038/s41598-024-80856-7.

Inflammation-Responsive Mesoporous Silica Nanoparticles with Synergistic Anti-inflammatory and Joint Protection Effects for Rheumatoid Arthritis Treatment.

Wu Y, Chen W, Zeng Y, Ji Q, Yang Y, Guo X Pharm Res. 2024; 41(7):1493-1505.

PMID: 38918308 DOI: 10.1007/s11095-024-03732-z.

Network pharmacology and experiment validation investigate the potential mechanism of triptolide in oral squamous cell carcinoma.

Hao P, Zhang P, Liu Y, Cao Y, Du L, Gao L Front Pharmacol. 2024; 14:1302059.

PMID: 38259290 PMC: 10800448. DOI: 10.3389/fphar.2023.1302059.

Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies.

Ji Z, Shen J, Lan Y, Yi Q, Liu H MedComm (2020). 2023; 4(4):e308.

PMID: 37441462 PMC: 10333890. DOI: 10.1002/mco2.308.

References

Huang J, Zhou L, Wu H, Pavlos N, Chim S, Liu Q . Triptolide inhibits osteoclast formation, bone resorption, RANKL-mediated NF-қB activation and titanium particle-induced osteolysis in a mouse model. Mol Cell Endocrinol. 2014; 399:346-53. DOI: 10.1016/j.mce.2014.10.016. View

Chen M, Wang J, Wang D, Wu R, Hou H . Triptolide inhibits migration and proliferation of fibroblasts from ileocolonic anastomosis of patients with Crohn's disease via regulating the miR‑16‑1/HSP70 pathway. Mol Med Rep. 2019; 19(6):4841-4851. PMC: 6522880. DOI: 10.3892/mmr.2019.10117. View

Yang J, Tang X, Ke X, Dai Y, Shi J . Triptolide Suppresses NF-κB-Mediated Inflammatory Responses and Activates Expression of Nrf2-Mediated Antioxidant Genes to Alleviate Caerulein-Induced Acute Pancreatitis. Int J Mol Sci. 2022; 23(3). PMC: 8835869. DOI: 10.3390/ijms23031252. View

Viegas J, Praca F, Kravicz M, Bentley M . Therapeutic applications and delivery systems for triptolide. Drug Deliv Transl Res. 2020; 10(6):1584-1600. DOI: 10.1007/s13346-020-00827-z. View

Ling D, Xia H, Park W, Hackett M, Song C, Na K . pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. ACS Nano. 2014; 8(8):8027-39. DOI: 10.1021/nn502074x. View

Wallace S, Oken M, Lunetta K, Panoskaltsis-Mortari A, Masellis A . Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer. 2001; 91(7):1219-30. DOI: 10.1002/1097-0142(20010401)91:7<1219::aid-cncr1122>3.0.co;2-1. View

He Q, Minn I, Wang Q, Xu P, Head S, Datan E . Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation. Angew Chem Int Ed Engl. 2016; 55(39):12035-9. DOI: 10.1002/anie.201606121. View

Jiang C, Fang X, Zhang H, Wang X, Li M, Jiang W . AMD3100 combined with triptolide inhibit proliferation, invasion and metastasis and induce apoptosis of human U2OS osteosarcoma cells. Biomed Pharmacother. 2016; 86:677-685. DOI: 10.1016/j.biopha.2016.12.055. View

Macheda M, Rogers S, Best J . Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2004; 202(3):654-62. DOI: 10.1002/jcp.20166. View

10.

Xie J, Bi Y, Zhang H, Dong S, Teng L, Lee R . Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application. Front Pharmacol. 2020; 11:697. PMC: 7251059. DOI: 10.3389/fphar.2020.00697. View

11.

Avdic D, Pecar D, Mujic-Skikic E, Pecar E . Osteoarthritis, application of physical therapy proceduers. Bosn J Basic Med Sci. 2006; 6(3):84-8. PMC: 7193664. DOI: 10.17305/bjbms.2006.3151. View

12.

Simpson E, Brown H . Understanding osteosarcomas. JAAPA. 2018; 31(8):15-19. DOI: 10.1097/01.JAA.0000541477.24116.8d. View

13.

Noel P, Von Hoff D, Saluja A, Velagapudi M, Borazanci E, Han H . Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol Sci. 2019; 40(5):327-341. DOI: 10.1016/j.tips.2019.03.002. View

14.

Zhou P, Sun X, Gong T, Zhang Z, Zhang L . Conjugating glucosamine to triptolide to enhance its protective effect against renal ischemia-reperfusion injury and reduce its toxicity. J Drug Target. 2019; 22(3):200-210. DOI: 10.3109/1061186X.2013.856011. View

15.

Wang C, Liu B, Xu X, Zhuang B, Li H, Yin J . Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine. Oncotarget. 2016; 7(7):8360-72. PMC: 4884998. DOI: 10.18632/oncotarget.7073. View

16.

Brinker A, Ma J, Lipsky P, Raskin I . Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry. 2007; 68(6):732-66. PMC: 3867260. DOI: 10.1016/j.phytochem.2006.11.029. View

17.

Gang W, Tanjun W, Yong H, Jiajun Q, Yi Z, Hao H . Inhibition of miR-9 decreases osteosarcoma cell proliferation. Bosn J Basic Med Sci. 2019; 20(2):218-225. PMC: 7202196. DOI: 10.17305/bjbms.2019.4434. View

18.

Fanelli M, Tavanti E, Patrizio M, Vella S, Fernandez-Ramos A, Magagnoli F . Cisplatin Resistance in Osteosarcoma: Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments. Front Oncol. 2020; 10:331. PMC: 7077033. DOI: 10.3389/fonc.2020.00331. View

19.

Qi Q, Li Q, Zhu H, Lu H, Yang X, Wu Y . Triptolide analog LLDT-8 ameliorates psoriasis-like dermatitis in BALB/c mice via suppressing the IL-36α signaling pathway. Pharmacol Res. 2021; 169:105678. DOI: 10.1016/j.phrs.2021.105678. View

20.

Young J, Jensen R, Hartvigsen J, Roos E, Ammendolia C, Juhl C . Prevalence of multimorbid degenerative lumbar spinal stenosis with knee or hip osteoarthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2022; 23(1):177. PMC: 8876450. DOI: 10.1186/s12891-022-05104-3. View